Tzu Chi University
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Aug 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 28, 2027The maintenance fee for Method for treateing or preventing ischemic optic neuropathy (US 11,826,340) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Use of a polyenylpyrrole derivative in preparation of anti-oral cancer drugs (US 10,500,188) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Vesicles comprising lectins expressed on the surface and methods of use thereof to deliver an agent to autophagic and apoptotic cells (US 10,584,154) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,123,694 | Optical measurement device and optical measurement system In force · From the USPTO record | In force | From the USPTO record | |
| US 10,584,154 | Vesicles comprising lectins expressed on the surface and methods of use thereof to deliver an agent to autophagic and apoptotic cells In force · From the USPTO record | In force | From the USPTO record | |
| US 11,007,176 | Use of actin depolymerizing agents for the treatment of anxiety disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 10,500,188 | Use of a polyenylpyrrole derivative in preparation of anti-oral cancer drugs In force · From the USPTO record | In force | From the USPTO record | |
| US 12,188,049 | Methods for mobilizing stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 11,730,667 | Wearable Stimulation Device for Stimulating Deep Muscles of Abdomen and Waist of Human Body In force · High confidence | In force | High confidence | |
| US 11,826,340 | Method for treateing or preventing ischemic optic neuropathy In force · From the USPTO record | In force | From the USPTO record | |
| US 12,129,279 | Antimicrobial Peptides and Use of the Same for Treating Microbial Infections In force · High confidence | In force | High confidence | |
| US 12,773,512 | Retaining Device for Medical Equipment In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 9 no status recorded